The financing removes near-term cash runway risk but dilutes existing shareholders. The data readout delay is a modest negative for near-term catalysts. Monitor Fall 2026 monotherapy data for dose cap impact on safety/efficacy — positive data could re-rate the stock. The warrant overhang at $3.289 may cap upside near that level.
Price Chart
Executive Summary
Pyxis Oncology announced a $50M private placement (plus up to $64M from warrants) led by BVF Partners, extending cash runway into Q2 2027. The company also pushed back its Phase 1 monotherapy data readout for MICVO in HNSCC to Fall 2026 and combination data to Q4 2026. The financing is dilutive but provides capital to advance the lead ADC program through key milestones.
Key Financial Metrics
Key Facts
- Private placement of 19,600,153 shares at $2.551/share, raising $50M upfront
- Warrants for equal number of shares at $3.289/share, potentially adding $64M if exercised
- Cash runway extended into Q2 2027
- Phase 1 monotherapy data for MICVO in 2L+ R/M HNSCC delayed to Fall 2026 (previously earlier)
- Phase 1/2 combination data with pembrolizumab now expected Q4 2026
- Financing led by BVF Partners with participation from GordonMD, RTW, and Coastlands Capital
- MICVO received Fast Track Designation from FDA for R/M HNSCC
Financial Impact
$50M upfront gross proceeds, plus up to $64M from warrants; dilution of ~19.6M shares (approx. 11% of pre-offering shares based on market cap of $175M and $2.551 price)
Risk Factors
- Dilution from 19.6M shares and potential additional dilution from warrant exercise
- Data readout delays reduce near-term catalyst visibility
- Clinical-stage biotech with no approved products — high binary risk on MICVO data
- Warrant exercise price at $3.289 may create resistance if stock approaches that level
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3319560 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $3.38 $3.34 | ▼ −1.18% | ▼ −0.09% | $2.19 (−35.21%) |
Sep 8, 2026 24d ago | 8-K | $3.89 $3.33 | ▼ −14.40% | ▼ −13.28% | $2.19 (−43.70%) |
Aug 28, 2026 5w ago | EFFECT | $3.23 $3.89 | ▼ −20.43% | ▼ −20.32% | $2.19 (+32.20%) |
Aug 13, 2026 7w ago | 8-K | $3.01 $3.12 | ▲ +3.65% | ▲ +5.62% | $2.19 (−27.24%) |
Jul 2, 2026 13w ago | 8-K | $2.63 $2.64 | ▲ +0.38% | ▼ −0.55% | $2.19 (−16.73%) |
Jun 30, 2026 13w ago | 144 | $2.85 $3.07 | ▲ +7.72% | ▲ +7.46% | $2.19 (−23.16%) |
Jun 30, 2026 13w ago | Press Release | $3.01 $2.46 | ▼ −18.27% | ▼ −18.88% | $2.19 (−27.24%) |
May 14, 2026 20w ago | 8-K | $2.21 $1.94 | ▼ −12.22% | ▼ −11.50% | $2.19 (−0.90%) |
May 14, 2026 20w ago | Press Release | $2.21 $1.94 | ▼ −12.22% | ▼ −11.50% | $2.19 (−0.90%) |
Apr 30, 2026 22w ago | DEFA14A | $1.70 $2.26 | ▲ +32.94% | ▲ +31.21% | $2.19 (+28.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access